Blog
RSS FeedPosted by Michael Wonder on 15 Mar 2023
Zanubrutinib in chronic lymphocytic leukaemia: additional benefit for certain patients
15 March 2023 - For adults with relapsed/refractory chronic lymphocytic leukaemia who have not yet received a BTK or BCL2 inhibitor, ...
Posted by Michael Wonder on 02 Mar 2023
Efficient RCTs with real world data for benefit assessments: accelerating evidence-based care
2 March 2023 - Together with colleagues from the Belgian HTA agency KCE, three employees of IQWiG in the BMJ are ...
Posted by Michael Wonder on 16 Feb 2023
Thomas Kaiser becomes the new head of IQWiG
16 February 2023 - The current head of the IQWiG department for drug assessment succeeds Jürgen Windeler, who is retiring after ...
Posted by Michael Wonder on 15 Feb 2023
Germany proposes to fix shortages in certain medicines
15 February 2023 - Germany's health ministry on Tuesday vowed to fix shortages in medicines for children, antibiotics and cancer ...
Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...
Posted by Michael Wonder on 26 Jan 2023
Draft methods (version 7.0): IQWiG is extending the comment period
26 January 2023 - The new deadline is 28 February 2023. ...
Posted by Michael Wonder on 03 Jan 2023
Pertuzumab and pertuzumab with trastuzumab in breast cancer: now a minor additional clinical benefit
2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of ...
Posted by Michael Wonder on 08 Dec 2022
IQWiG updates its General Methods
6 December 2022 - Revision of the cost-benefit assessment and addition of the concept of application-accompanying data collection: Comments on ...
Posted by Michael Wonder on 08 Dec 2022
Osteoporosis after menopause: fewer vertebral fractures with teriparatide than with risedronate
5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab ...
Posted by Michael Wonder on 07 Dec 2022
Differences in evidentiary requirements between European Medicines Agency and European health technology assessment of oncology drugs—can alignment be enhanced?
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...
Posted by Michael Wonder on 06 Dec 2022
Germany's use of reference pricing for biologics: lessons for the US
5 December 2022 - A redesign of consumer cost sharing in the US is important to accelerate the adoption of biosimilars ...
Posted by Michael Wonder on 01 Dec 2022
Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
Posted by Michael Wonder on 03 Nov 2022
Advanced cervical cancer: pembrolizumab prolongs life
2 November 2022 - There is a hint of a major added benefit compared to chemotherapy with cisplatin or carboplatin, each ...
Posted by Michael Wonder on 27 Oct 2022
Evidence based drug delivery for rare diseases: the role of digitisation
25 October 2022 - Digitisation has potential when it comes to making clinical development for the care of rare diseases more ...
Posted by Michael Wonder on 26 Oct 2022
Germany significantly tightens drug pricing and reimbursement laws
26 October 2022 - The German regulation of pricing and reimbursement of pharmaceuticals is probably one of the most complicated legal ...